Finvest
GNW Insurance · Mortgage insurance · Long-term care · Turnaround · Thesis updated July 19, 2026

Enact funds the repair job

01 Running thesis

A valuable stake, plus old risk

Genworth is a sum of parts story. The cleanest part is Enact, its majority-owned mortgage insurance company. Enact is profitable, public, and sent $99 million of capital returns to Genworth Holdings in Q1 2026.

The hard part is the Closed Block. This is the old long-term care, life, and annuity business that Genworth no longer actively sells. The company has worked for years to raise premiums or reduce benefits on older long-term care policies. That plan has produced about $34.5 billion of cumulative economic benefit, but management still has about $5.0 billion left to achieve.

The bull case is that investors give Genworth more credit for Enact and less punishment for the Closed Block over time. CareScout adds a possible growth leg, especially if SeniorLeaf and Care Assurance can bring in real revenue.

The bear case is simple. Enact is tied to the housing cycle, the Closed Block still has tail risk, and CareScout needs money before it proves scale. CareScout Services alone is expected to need about $50 million to $55 million of investment in 2026.

May 2026Q1 2026 kept the thesis balanced. Enact returned $99 million, but long-term care rate approvals were modest in Q1 and the Closed Block still needs more work.
May 2026The Q1 2026 Form 10-Q confirmed CareScout network progress, including about 97% coverage of the age 65 and over U.S. census population across all 50 states.
Feb 2026The 2025 Form 10-K made the story clearer by reorganizing reporting into Enact and Closed Block. Enact returned $407 million in 2025, and the long-term care rate plan reached about $34.5 billion of cumulative benefit.
Nov 2025Genworth launched CareScout Care Assurance in October 2025, moving the product from plan to market test. The next question became adoption and sales productivity.
Jul 2025Q2 2025 showed steady execution. Enact returned $94 million, the long-term care benefit rose to about $31.6 billion, and Care Assurance approvals expanded.
May 2025Q1 2025 was incremental but positive. Enact returned $76 million, and Care Assurance received broad regulatory approval ahead of launch.
Feb 2025The 2024 Form 10-K strengthened the growth case. Enact returned $289 million in 2024, and Genworth committed capital to CareScout Insurance.
Nov 2024Q3 2024 supported the same thesis. Enact capital returns were expected at the high end of guidance, the long-term care rate plan reached about $30 billion, and CareScout's provider network expanded.
02 Business model

Cash from mortgages, risk from care

Genworth makes money mostly from insurance premiums and investment income. In Q1 2026, consolidated revenue was $1.777 billion. Premiums were $881 million, and net investment income was $766 million.

Enact sells private mortgage insurance. Lenders use this insurance when a borrower has a smaller down payment. Enact earns premiums, pays claims when insured borrowers default, and returns excess capital through dividends and buybacks.

The Closed Block is different. It is a runoff book, which means Genworth is not trying to grow it. It is trying to make sure the old policies can pay claims without needing fresh parent capital. That depends on reserves, investment returns, claims experience, and more rate approvals from state regulators.

CareScout sits in Corporate and Other. It offers fee-based aging care services and a newer long-term care insurance product called Care Assurance. The idea is to build a lower-risk aging care platform, but it is still early and still consuming cash.

03 Product portfolio

What Genworth sells or manages

Cash cow

Enact mortgage insurance

Enact provides private mortgage insurance to lenders and investors. It is the main earnings engine and returned $99 million to Genworth Holdings in Q1 2026.

Option

CareScout aging care services

CareScout offers fee-based aging care support through the CareScout Quality Network. In Q1 2026, the network covered about 97% of the age 65 and over U.S. census population across all 50 states.

Option

SeniorLeaf senior living placement

SeniorLeaf adds senior living placement to CareScout's home care network. The key question is whether the acquired platform can bring revenue and margins, not only a bigger network.

Growth engine

CareScout Care Assurance

Care Assurance is Genworth's newer long-term care insurance product, launched in October 2025. A worksite version is planned for later in 2026, which could open an employer sales channel.

Steady

Legacy long-term care insurance

This is the largest and most sensitive part of the Closed Block. Genworth no longer actively sells these old policies, but it must keep paying valid claims.

Steady

Legacy life insurance and annuities

These are older in-force blocks that are also in runoff. They can still affect earnings, capital, and reported volatility.

04 Business segments

Q1 mix shows the drag

Enact18%modest
Closed Block58%declining
Corporate and Other24%growing fast

Segment shares use Q1 2026 total revenue disclosed in the Form 10-Q and financial supplement context: Enact $312 million, Closed Block $1.037 billion, and Corporate and Other $428 million. Revenue mix does not equal value mix, since Enact produced positive adjusted operating income while the Closed Block lost money.

05 Risk factors

What could break the thesis

Closed Block is not self-sustaining

High impact · Medium odds

The old long-term care policies are the main balance sheet risk. Genworth has achieved about $34.5 billion of cumulative economic benefit from rate increases and benefit reductions, but about $5.0 billion remains. If approvals slow or claims run worse than expected, losses could grow.

We watchQuarterly updates to the long-term care rate action plan, especially gross incremental premium approvals and the remaining economic benefit target.

Enact capital returns slow

High impact · Medium odds

Genworth relies on Enact to send cash to the holding company. That cash helps fund CareScout, buybacks, and debt actions. A housing downturn, higher unemployment, or mortgage insurance capital rules could reduce Enact's ability to send money up.

We watchEnact capital returns, PMIERs sufficiency, delinquencies, and the loss ratio.

CareScout burns cash without scale

Medium impact · Medium odds

CareScout is the growth story, but it is still young. CareScout Services is expected to need about $50 million to $55 million of investment in 2026. If customer demand is weak or provider credentialing is slow, the business may stay costly for longer.

We watchCareScout revenue, first sales figures for Care Assurance, worksite launch progress, and SeniorLeaf integration milestones.

Mortgage insurance cycle turns

Medium impact · Medium odds

Enact benefits when borrowers keep paying and home prices support recoveries. If unemployment rises or home prices fall, more insured loans could become claims. That would pressure earnings and capital returns.

We watchNew delinquencies, cure rates, home price trends, and unemployment.

Absa litigation recovery is delayed or lost

Medium impact · Low odds

The bull case includes a possible litigation recovery that management has discussed as potentially meaningful. The internal thesis tracks a possible $750 million recovery. Appeals can take time, and the final amount could be lower or zero.

We watchCourt updates on the Absa litigation appeal and any stated plan for using proceeds.
06 Quick answers

In one breath

Why is Genworth stock tied to Enact?

Genworth owns a majority stake in Enact, a public mortgage insurer. Enact is the clearest source of profit and parent-company cash, including $99 million returned in Q1 2026.

What is the Closed Block at Genworth?

The Closed Block is Genworth's old long-term care, life, and annuity business. These policies are no longer actively sold, but they still create claims, reserves, and earnings risk.

What is CareScout?

CareScout is Genworth's aging care growth platform. It includes care services, a provider network, senior living placement through SeniorLeaf, and the newer Care Assurance long-term care product.

What should investors watch next?

Watch Enact capital returns, long-term care rate approvals, and early Care Assurance sales data. The worksite product launch later in 2026 is a key test.